Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

1. Clinical Practice Guidelines – Thyroid cancer

Clinical Practice Guidelines – Thyroid cancer SPECIAL ARTICLE Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † S. Filetti 1 , C. Durante 1 , D. Hartl 2,3 , S. Leboulleux 3,4 , L. D. Locati 5 , K. Newbold 6 , M. G. Papotti 7 & A. Berruti 8 , on behalf of the ESMO Guidelines Committee * 1 Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 2 Department of Head and Neck Oncology, Gustave Roussy, Villejuif; 3 (...) Civili, Brescia, Italy Key words: papillary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, medullary thyroid cancer, management Introduction The aim of clinical practice guidelines is to provide physicians with the best available evidence on particular issues and recom- mendations for the best standards of care. They help health pro- fessionals weigh the bene?ts and the risks of available diagnostic or therapeutic options. Randomised clinical trial (RCT) data on the management

2020 European Society for Medical Oncology

2. A Double-Blind, Randomized Controlled Trial of Pre-incision Wound Infiltration Using Diclofenac Versus Bupivacaine for Post-operative Pain Relief in Open Thyroid and Parathyroid Surgery

A Double-Blind, Randomized Controlled Trial of Pre-incision Wound Infiltration Using Diclofenac Versus Bupivacaine for Post-operative Pain Relief in Open Thyroid and Parathyroid Surgery A Double-Blind, Randomized Controlled Trial of Pre-incision Wound Infiltration Using Diclofenac Versus Bupivacaine for Post-operative Pain Relief in Open Thyroid and Parathyroid Surgery - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation World J Surg Actions . 2020 Mar 19. doi: 10.1007/s00268-020-05458-6. Online ahead of print. A Double-Blind, Randomized Controlled Trial of Pre-incision Wound Infiltration Using Diclofenac Versus Bupivacaine for Post-operative Pain Relief in Open Thyroid and Parathyroid Surgery , , , Affiliations Expand Affiliations 1 Department of Surgery, University

2020 EvidenceUpdates

3. BTA/SFE statement regarding issues specific to thyroid dysfunction during the COVID -19 pandemic

BTA/SFE statement regarding issues specific to thyroid dysfunction during the COVID -19 pandemic v1 25th March 2020 BTA/SFE statement regarding issues specific to thyroid dysfunction during the COVID -19 pandemic The worldwide spread of the novel coronavirus, COVID-19, has recently been declared a pandemic. This presents many challenges to those of us working in healthcare, and will especially impact individuals with some chronic conditions. Members of the British Thyroid Association (BTA (...) ) and the Society for Endocrinology (SfE) have received numerous queries regarding how this pandemic may affect management of patients with thyroid disease, so we have formulated responses to these questions in order to assist our endocrine and primary care colleagues during this extraordinary time. We acknowledge that the situation is changing rapidly and also that local practice may differ depending on available resources and infrastructure. The British Thyroid Foundation (BTF) and Thyroid Cancer Forum-UK

2020 British Thyroid Association

4. Joint statement from the Society for Endocrinology and the British Thyroid Association regarding ‘Association of Radioactive Iodine Treatment with cancer mortality in patients with hyperthyroidism’

Joint statement from the Society for Endocrinology and the British Thyroid Association regarding ‘Association of Radioactive Iodine Treatment with cancer mortality in patients with hyperthyroidism’ 266 | wileyonlinelibrary.com/journal/cen Clinical Endocrinology. 2020;92:266–267. © 2019 John Wiley & Sons Ltd Received: 1 November 2019 | Revised: 27 November 2019 | Accepted: 29 November 2019 DOI: 10.1111/cen.14136 LE T TER TO THE EDITOR Joint statement from the Society for Endocrinology (...) and the British Thyroid Association regarding ‘Association of Radioactive Iodine Treatment with cancer mortality in patients with hyperthyroidism’ We are aware of the substantial interest shown in the recent publica - tion in JAMA internal medicine by Kitahara et al 1 This retrospective analysis of data from the large multicentre co-operative thyrotoxico- sis therapy follow-up study (CTTFUS) suggests a modest increase in potential risk of death from cancer in people who receive radioiodine therapy

2020 British Thyroid Association

5. Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma

Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma Recurrence Following Hemithyroidectomy in Patients With Low- And Intermediate-Risk Papillary Thyroid Carcinoma - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National (...) Cancel Actions Cite Share Permalink Copy Page navigation Br J Surg Actions . 2020 Feb 5. doi: 10.1002/bjs.11430. Online ahead of print. Recurrence Following Hemithyroidectomy in Patients With Low- And Intermediate-Risk Papillary Thyroid Carcinoma , , Affiliations Expand Affiliation 1 Department of Otolaryngology - Head and Neck Surgery, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu, 41944, Korea. PMID: 32026467 DOI: Item in Clipboard Recurrence Following Hemithyroidectomy in Patients

2020 EvidenceUpdates

6. Teprotumumab (Tepezza) - Thyroid eye disease

Teprotumumab (Tepezza) - Thyroid eye disease Drug Approval Package: TEPEZZA TEPEZZA " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TEPEZZA Company: Horizon Therapeutics Ireland DAC Application Number: 761143 Approval Date: 01/21/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

7. Thyroid disease: assessment and management

Thyroid disease: assessment and management Thyroid disease: assessment and management NICE guideline Published: 20 November 2019 www.nice.org.uk/guidance/ng145 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Thyroid disease: assessment and management (NG145) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 53Contents Contents Overview 5 Who is it for? 5 Recommendations 6 1.1 Information for people

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

8. Thyroid hormones treatment for subclinical hypothyroidism Full Text available with Trip Pro

Thyroid hormones treatment for subclinical hypothyroidism Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline | The BMJ Intended for healthcare professionals Username * Password * Edition: Search form Search Search Thyroid hormones... Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline (Published 14 May 2019) Cite this as: BMJ 2019;365:l2006 Visual summary of recommendation or No thyroid hormones Thyroid hormones (...) Levothyroxine Interventions compared Recommendation Population Adults with subclinical hypothyroidism Does not apply to: May not apply to: Including: Women who are or trying to become pregnant Patients with no symptoms (diagnosed after screening) Patients with non-specific symptoms Patients with severe symptoms Patients with TSH above 20 mIU/L Young adults (such as <30 years) Elevated levels of thyroid stimulating hormone (TSH) Normal free T4 (thyroxine) levels We recommend against thyroid hormone therapy

2019 BMJ Rapid Recommendations

9. Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V

Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Lenvatinib (Schilddrüsenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 May 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-19 Lenvatinib (...) (thyroid carcinoma) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-19 Version 1.0 Lenvatinib (thyroid carcinoma) 13 May 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Lenvatinib (thyroid carcinoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 15 February 2019

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

10. Does the ATA Risk Stratification Apply to Patients with Papillary Thyroid Microcarcinoma? (Abstract)

Does the ATA Risk Stratification Apply to Patients with Papillary Thyroid Microcarcinoma? The incidence of papillary thyroid microcarcinoma (PTMC) has increased over the past decade. The American Thyroid Association (ATA) suggests that these patients may undergo either thyroid lobectomy or active surveillance. It remains unclear whether there exists a subgroup of PTMC patients who may benefit from more aggressive treatment due to increased risk of recurrence.We retrospectively reviewed 357

2019 EvidenceUpdates

11. Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care

Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care Richard Birtwhistle , Kate Morissette , James A. Dickinson , Donna L. Reynolds , Marc T. Avey , Francesca Reyes Domingo , Rachel Rodin (...) of Family Medicine and Community Health Sciences (Dickinson), University of Calgary, Alta.; Dalla Lana School of Public Health and Department of Family and Community Medicine (Reynolds), University of Toronto, Ont.; Department of Psychiatry (Thombs), Jewish General Hospital and McGill University, Montréal, Que. KEY POINTS The Canadian Task Force on Preventive Health Care strongly recommends against screening for thyroid dysfunction in asymptomatic nonpregnant adults. Screening for thyroid dysfunction

2019 Canadian Task Force on Preventive Health Care

12. Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer (Abstract)

Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer Current guidelines recommend that women delay pregnancy for 6 to 12 months after the receipt of radioactive iodine treatment (RAIT) following thyroidectomy for differentiated thyroid carcinoma. Although concerns exist regarding the risks associated with pregnancy after RAIT, no large-scale study, to date, has investigated the association between RAIT and pregnancy (...) outcomes.To investigate whether RAIT was associated with increases in adverse pregnancy outcomes among South Korean women who received RAIT after thyroidectomy for thyroid cancer and to evaluate the appropriate interval between RAIT and conception.This population-based cohort study used the Health Insurance Review and Assessment database of South Korea to identify a total of 111 459 women of childbearing age (20-49 years) who underwent thyroidectomy for the treatment of differentiated thyroid carcinoma

2019 EvidenceUpdates

13. Thyroid Cancer

Thyroid Cancer Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † S. Filetti 1 , C. Durante 1 , D. Hartl 2 , S. Leboulleux 3 , L.D. Locati 4 , K. Newbold 5 , M.G. Papotti 6 , A. Berruti 7 , on behalf of the ESMO Guidelines Committee* 1 Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy; 2 Department of Head and Neck Oncology, Gustave Roussy and Université Paris Saclay, Villejuif; 3 Department of Nuclear (...) : clinicalguidelines@esmo.org † Approved by the ESMO Guidelines Committee: February 2008, last update September 2019. This publication supersedes the previously published version—Ann Oncol 2012; 23 (Suppl. 7): vii110–vii119. Running header: ESMO Clinical Practice Guidelines thyroid cancer Word count: 11 701 (excluding key message, references, tables & figures) Key words: papillary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, medullary thyroid cancer, management Key message (online only): ©

2019 European Society for Medical Oncology

14. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. Full Text available with Trip Pro

Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. To explore whether thyroid stimulating hormone (TSH) concentration in patients with a diagnosis of hypothyroidism is associated with increased all cause mortality and a higher risk of cardiovascular disease and fractures.Retrospective cohort study.The Health Improvement Network (THIN), a database of electronic patient records from UK primary

2019 BMJ

15. Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system Full Text available with Trip Pro

Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system The AJCC/UICC classification is widely used for predicting survival in papillary thyroid cancer (PTC), but has not been evaluated as a predictor of recurrence. The hypothesis of this study was that the eighth edition of the AJCC system can be used in this novel way.All patients in the study underwent surgery for PTC at a high-volume endocrine surgery centre in France between 1985 and 2015

2019 EvidenceUpdates

16. Thyroxine replacement for subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism. (Abstract)

Thyroxine replacement for subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism. Thyroid disease is the second most common endocrine disorder affecting women of reproductive age. Subclinical hypothyroidism is diagnosed by an elevated thyroid-stimulating hormone concentration with a normal concentration of free thyroxine hormone. Autoimmune thyroid disease (ATD) is diagnosed by the presence of thyroid autoantibodies, regardless of thyroid hormone levels (...) . Thyroxine may be a useful treatment for subfertile women with these two specific types of thyroid disease for improving pregnancy outcomes during assisted reproduction.To evaluate the efficacy and harms of levothyroxine replacement in subfertile women with subclinical hypothyroidism or with normal thyroid function and thyroid autoimmunity (euthyroid autoimmune thyroid disease, or euthyroid ATD) undergoing assisted reproduction.We searched the Cochrane Gynaecology and Fertility (CGF) Group specialised

2019 Cochrane

17. A Perioperative Small Dose of Dexamethasone Enhances Postoperative Recovery by Reducing Volume and Inflammatory Contents in Wound Drainage After Thyroid Surgery: A Double-Blinded, Randomized, Prospective Study (Abstract)

A Perioperative Small Dose of Dexamethasone Enhances Postoperative Recovery by Reducing Volume and Inflammatory Contents in Wound Drainage After Thyroid Surgery: A Double-Blinded, Randomized, Prospective Study The aims of this study were to assess the effect of perioperative dexamethasone on postoperative thyroid surgery recovery using measures of wound drainage volume and C-reactive protein (CRP) levels and leukocyte counts.From January to September 2014, healthy patients, aged between 18 (...) and 65 years, had elective thyroid surgery in the tertiary hospital. Eligible patients were randomized into either group D (dexamethasone 0.1 mg/kg IV) or group S (saline IV) after anesthesia induction. At the end of surgery, a drainage tube was placed at the thyroid bed with a negative pressure ball connected outside the wound. Drainage fluids were collected after thyroid surgery. The fluid volume and the levels of C-reactive protein and leukocyte counts inside were analyzed. All patients were

2019 EvidenceUpdates

18. Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. Full Text available with Trip Pro

Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. Thyroid peroxidase antibodies are associated with an increased risk of miscarriage and preterm birth, even when thyroid function is normal. Small trials indicate that the use of levothyroxine could reduce the incidence of such adverse outcomes.We conducted a double-blind, placebo-controlled trial to investigate whether levothyroxine treatment would increase live-birth rates among euthyroid women who had thyroid (...) peroxidase antibodies and a history of miscarriage or infertility. A total of 19,585 women from 49 hospitals in the United Kingdom underwent testing for thyroid peroxidase antibodies and thyroid function. We randomly assigned 952 women to receive either 50 μg once daily of levothyroxine (476 women) or placebo (476 women) before conception through the end of pregnancy. The primary outcome was live birth after at least 34 weeks of gestation.The follow-up rate for the primary outcome was 98.7% (940 of 952

2019 NEJM Controlled trial quality: predicted high

19. High-intensity focused ultrasound for symptomatic benign thyroid nodules

High-intensity focused ultrasound for symptomatic benign thyroid nodules High-intensity focused ultr High-intensity focused ultrasound for asound for symptomatic benign th symptomatic benign thyroid nodules yroid nodules Interventional procedures guidance Published: 27 February 2019 nice.org.uk/guidance/ipg643 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) ultrasound for symptomatic benign thyroid nodules raises no major safety concerns, however the current evidence on its efficacy is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 4governance, consent, and audit or research. 1.2 Clinicians wishing to do high-intensity focused ultrasound

2019 National Institute for Health and Clinical Excellence - Interventional Procedures

20. Repeat thyroid function tests for healthy older people are not needed. (Abstract)

Repeat thyroid function tests for healthy older people are not needed. The studyRoberts L, McCahon D, Johnson O, Haque MS, Parle J, Hobbs FR. Stability of thyroid function in older adults: the Birmingham Elderly Thyroid Study. Published on 28 August 2018 Br J Gen Pract 2018;68:e718-26.This study was funded by the National Institute for Health Research School for Primary Care Research (SPCR).To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000703/repeat-thyroid

2019 BMJ